The September 2026 DAYBREAK readout is the dominant near-term catalyst — positive non-inferiority data for Zenkuda or KSI-501 vs aflibercept could unlock a multi-billion dollar anti-VEGF market opportunity. Monitor for any pre-read or data leaks ahead of the expected topline release. Cash runway into 2027 provides a buffer, but a negative readout would likely force a dilutive financing or strategic alternative.
Price Chart
Executive Summary
Kodiak Sciences reported Q2 2026 net loss of $65.6M ($1.05/share), wider than the $54.3M loss in Q2 2025, with R&D spending up 31% to $56.1M as clinical activities ramp. The stock's primary catalyst is the upcoming September 2026 DAYBREAK Phase 3 topline data for Zenkuda and KSI-501 in wet AMD, followed by December 2026 PEAK data for KSI-101 in MESI. Cash of $125.9M is expected to fund operations into 2027, but the widening loss and lack of revenue make this a binary event-driven pre-commercial biotech story.
Key Financial Metrics
Key Facts
- Net loss Q2 2026: $65.6M ($1.05/share) vs $54.3M ($1.03/share) in Q2 2025
- Cash and cash equivalents: $125.9M as of June 30, 2026
- R&D expenses: $56.1M in Q2 2026, up from $42.8M in Q2 2025
- DAYBREAK Phase 3 topline data (Zenkuda & KSI-501) expected September 2026
- PEAK Phase 3 Pivotal Analysis 1 topline data (KSI-101) expected December 2026
- ALTO Phase 3 study (KSI-501 in DME) now enrolling patients
- BLA preparation activities for Zenkuda ongoing
- No revenue reported; company is pre-commercial
Financial Impact
Net loss widened by $11.3M YoY to $65.6M; cash burn rate ~$42M/quarter based on $125.9M cash vs $209.9M at year-end 2025
Risk Factors
- Phase 3 DAYBREAK study fails to meet non-inferiority primary endpoint
- Cash runway only into 2027; potential need for dilutive financing if development timelines slip
- Regulatory or manufacturing delays for Zenkuda BLA submission
- Competitive landscape: existing anti-VEGF therapies (aflibercept, faricimab) with established market positions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302851311 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $41.35 $33.14 | ▼ −19.85% | ▼ −17.86% | $94.45 (+128.42%) |
Aug 13, 2026 7w ago | Press Release | $41.35 $33.14 | ▼ −19.85% | ▼ −17.86% | $94.45 (+128.42%) |
Jun 11, 2026 16w ago | Institutional Cluster | $33.97 $40.08 | ▲ +17.99% | ▲ +16.10% | $94.45 (+178.04%) |
May 7, 2026 21w ago | 8-K | $41.01 $31.05 | ▼ −24.29% | ▼ −24.31% | $94.45 (+130.31%) |
Mar 31, 2026 26w ago | 8-K | $42.81 $43.67 | ▲ +2.01% | ▼ −7.71% | $94.45 (+120.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access